Caribou Biosciences (CRBU) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Caribou Biosciences (NASDAQ: CRBU):

• 10/15/2026 – Caribou Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/8/2026 – Caribou Biosciences was downgraded by HC Wainwright from “buy” to “neutral”.
• 10/7/2026 – Caribou Biosciences was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $1.00 price target on the stock.
• 10/7/2026 – Caribou Biosciences had its “market perform” rating reaffirmed by Leerink Partners. They now have a $1.00 price target on the stock, down from $4.00.
• 10/7/2026 – Caribou Biosciences was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $1.00 price target on the stock.
• 10/7/2026 – Caribou Biosciences was downgraded by Brookline Capital Markets from “buy” to “hold”.
• 9/19/2026 – Caribou Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments.

Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.